The stock of CVS Health Corporation (NYSE:CVS) decreased by -$0.08 on Monday to finish at $67.24, down -0.12 percent. The last five days have seen an average of 7,099,680 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$25.95. The average number of shares traded over the last 20 days was 10,275,275, while the average volume over the last 50 days totaled 9,609,204.
CVS stock dropped -9.88% since last month. On 08/17/23, the company’s shares reached a one-month low of $64.62. The stock touched a high of $104.83 on 01/04/23, after rallying from a low of $64.62 in 52 weeks. The price of CVS stock has declined by -27.85% or -$25.95 this year, reaching a new high 2 times. Still, the stock price is down -35.86% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CVS stock investors should be aware that CVS Health Corporation (CVS) stock had its last reported insider trading activity 26 days ago on Aug 03. On Aug 03, SVP, Cont & Chief Acct Officer Clark James David sold 25,759 shares at $74.92 each. This transaction resulted in the insider making $1,930,004. On May 03, Lynch Karen S added 14,000 shares at a price of US$69.75. After the transaction, the insider now owns 431,392 shares. EVP & General Counsel Moriarty Thomas M had earlier sold 137,466 shares on Dec 15 for $98.36 a share. The transaction was completed for $13,521,180.
Valuation Metrics
CVS Health Corporation (CVS) has a trailing price-to-earnings (P/E) ratio of 29.52. Beta for the stock is 0.61. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 0.25, the price-to-book (PB) ratio of 1.19, and the price-to-cash flow ratio of 4.83.
Company paid $0.6050 per share in dividends, remained unchanged from $0.6050 last year. A $0.0550 dividend increase was reported on Thursday December 15 2022.
Financial Health
For the three months ended June 29, CVS Health Corporation’s quick ratio was 0.60, while its current ratio was 0.90, indicating its inability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.84, and the total debt to equity ratio is 0.88. As far as profitability goes, gross margin for the trailing twelve months is 39.00% percent. CVS Health Corporation’s EBITDA margin for the year ended June 29 was 6.40%, whereas its operating margin stood at 1.90% for the same period. Based on annual data, it had gross profit of $125.58 billion and revenue of $322.47 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CVS’s return on assets (ROA) during the last 12 months has been 1.20%. There was a 5.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 4.10%.
Earnings Surprise
According to CVS Health Corporation’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $88.92 billion, while revenues rose by 9.32% to $85.28 billion. It was predicted that CVS Health Corporation’s quarterly earnings would be $2.21, but it ended up being $2.11, beating the consensus by 4.70%. EBITDA was $4.34 billion for the quarter. At the end of CVS Health Corporation’s most recent quarter ended June 29, its liabilities totaled 177.07 billion, while its total debt was $82.14 billion. Equity owned by shareholders amounts to $1.28 billion.
Technical Picture
Here’s a quick look at CVS Health Corporation’s (CVS) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 30.85%, suggesting the stock is Neutral, with a 42.63% historical volatility rate.
The stochastic %K and %D were 22.34% and 20.04% respectively, while the average true range (ATR) was 1.60. Based on the 14-day stochastic reading of 24.42%, the RSI (14) reading is 34.71%. On the 9-day MACD Oscillator, the stock is at -0.53, and the 14-day reading is at -2.91.
Analyst Ratings
CVS Health Corporation (NYSE: CVS) was downgraded by Edward Jones to a a Hold rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned CVS Health Corporation (CVS) an Overweight rating. CVS is a stock that is recommended for selling by 0 brokerage firms, while 8 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 2 rates it overweight and 17 others recommend it as a buy.
What is CVS’s price target for the next 12 months?
The current consensus forecast for the stock is between $76.00 and $110.00, with a median target price of $90.45. In analyzing these forecasts, the average price target given by analysts for CVS Health Corporation (CVS) is $92.16.
